Edwards Lifesciences Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Edwards Lifesciences Corp.
This edition of Medtech Insight’s Cardiovascular Catch-Up features highlights from recent interviews with leaders of some not-so-famous companies addressing cardiovascular health from a variety of angles – from improving the traditional stethoscope to non-invasive 3D mapping of arrhythmias and more.
The annual J.P. Morgan Healthcare Conference saw major medtech companies describe their experiences in 2021 and expectations for 2022 as they continue to cope with COVID-19.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the first day of the meeting.
The new device combines Edwards’ market-leading Sapien 3 transcatheter heart valve with its Alterra adaptive prestent device to treat patients with severe pulmonary regurgitation due to congenital valve defects.
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- CardiAQ Valve Technologies, Inc.
- CAS Medical Systems, Inc.
- Embrella Cardiovascular, Inc.
- Harpoon Medical, Inc.
- Percutaneous Valve Technologies, Inc.
- Valtech Cardio, Ltd.